Novel Boron-Rich Peptides Show Enhanced Stability, Potentially Activating Ghrelin Receptor
Background
The ghrelin receptor (GHSR1a) plays a crucial role in regulating appetite, energy homeostasis, and metabolism. Peptides targeting this receptor hold therapeutic promise for conditions like obesity or cachexia, but their clinical utility is often limited by poor metabolic stability and short half-lives in vivo. Therefore, developing stable, potent ghrelin receptor agonists with improved pharmacokinetic properties is a significant challenge in drug discovery.
Results
The study successfully identified several boron-rich peptides that exhibited potent activation of the ghrelin receptor. The most promising lead compound, Boro-Ghrelin-1, demonstrated a high binding affinity with an IC50 of 5 nM, comparable to native ghrelin's IC50 of 4 nM. Furthermore, this compound showed robust functional activity, activating the receptor with an EC50 of 10 nM, only slightly less potent than ghrelin's EC50 of 8 nM. Importantly, the incorporation of the meta-carborane significantly enhanced metabolic stability: > Boro-Ghrelin-1 exhibited a 3-fold increase in serum half-life, remaining stable for over 72 hours in human serum, compared to native ghrelin which degraded by 90% within 24 hours. Selectivity assays confirmed no significant activity at 100-fold higher concentrations for related G-protein coupled receptors.
Why It Matters
This research demonstrates that incorporating a meta-carborane scaffold can effectively improve the metabolic stability of peptide agonists without compromising their potency or selectivity for the ghrelin receptor. This enhanced stability is a critical factor for developing orally bioavailable or long-acting injectable peptide therapeutics. These novel boronated peptides represent a promising new class of compounds that could lead to more effective treatments for metabolic disorders like obesity, type 2 diabetes, or cachexia. The next logical steps involve conducting in vivo efficacy and safety studies in animal models, followed by toxicology assessments, paving the way for potential Phase I human trials.